Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

Ionis Pharmaceuticals (IONS) Long-Term Debt Repayments (2016 - 2024)

Ionis Pharmaceuticals (IONS) has disclosed Long-Term Debt Repayments for 13 consecutive years, with $44.5 million as the latest value for Q4 2024.

For Q4 2024, Long-Term Debt Repayments changed N/A year-over-year to $44.5 million; the TTM value through Dec 2024 reached $112.3 million, up 65.64%, while the annual FY2024 figure was $44.5 million, 90.88% down from the prior year.
Long-Term Debt Repayments hit $44.5 million in Q4 2024 for Ionis Pharmaceuticals, down from $67.8 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $67.8 million in Q3 2023 and bottomed at -$37000.0 in Q2 2021.
Average Long-Term Debt Repayments over 3 years is $41.3 million, with a median of $48.7 million recorded in 2021.